NewcelX Ltd

NCEL

Market cap $17.5M

Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND Meeting Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND Meeting

The appointment follows  New c elX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101 , providing a clear regulatory pathway toward clinical trials

FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart

Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX's platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including MS

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug (“Pre-IND”) briefing package to the U.S. Food and Drug Administration (“FDA”) to support the proposed First-In-Human (“FIH”) clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (“Eledon”; Nasdaq: ELDN).

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy.

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the Company's common shares on March 31, 2026.

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN), a clinical-stage immunology company with a focus on transplant medicine.

Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset ZURICH, Feb. 12, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in Clinical Drug Investigation, a Springer Nature journal.